Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. lowered its position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 33.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 163,113 shares of the biotechnology company's stock after selling 80,515 shares during the period. JPMorgan Chase & Co. owned 0.76% of Enanta Pharmaceuticals worth $938,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of ENTA. Assenagon Asset Management S.A. increased its holdings in shares of Enanta Pharmaceuticals by 34.1% in the 4th quarter. Assenagon Asset Management S.A. now owns 192,856 shares of the biotechnology company's stock valued at $1,109,000 after acquiring an additional 49,050 shares during the last quarter. Barclays PLC boosted its holdings in Enanta Pharmaceuticals by 294.2% in the third quarter. Barclays PLC now owns 27,438 shares of the biotechnology company's stock valued at $285,000 after purchasing an additional 20,478 shares in the last quarter. Geode Capital Management LLC increased its stake in Enanta Pharmaceuticals by 3.1% in the third quarter. Geode Capital Management LLC now owns 477,351 shares of the biotechnology company's stock valued at $4,946,000 after purchasing an additional 14,575 shares during the last quarter. AlphaQuest LLC raised its holdings in Enanta Pharmaceuticals by 16.4% during the fourth quarter. AlphaQuest LLC now owns 22,260 shares of the biotechnology company's stock worth $128,000 after purchasing an additional 3,137 shares in the last quarter. Finally, Thrivent Financial for Lutherans purchased a new stake in shares of Enanta Pharmaceuticals during the 4th quarter worth approximately $254,000. Hedge funds and other institutional investors own 94.99% of the company's stock.

Enanta Pharmaceuticals Stock Performance

Enanta Pharmaceuticals stock traded down $0.10 during midday trading on Friday, hitting $5.95. 101,428 shares of the company's stock were exchanged, compared to its average volume of 287,070. The firm's 50 day simple moving average is $5.91 and its 200 day simple moving average is $7.10. Enanta Pharmaceuticals, Inc. has a 12-month low of $4.09 and a 12-month high of $17.24. The stock has a market cap of $126.93 million, a price-to-earnings ratio of -1.20 and a beta of 0.81.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last released its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative return on equity of 75.53% and a negative net margin of 157.57%. On average, equities research analysts forecast that Enanta Pharmaceuticals, Inc. will post -4.65 EPS for the current fiscal year.

Insider Activity

In other news, CEO Jay R. Luly purchased 45,000 shares of the business's stock in a transaction that occurred on Wednesday, February 12th. The stock was purchased at an average cost of $5.69 per share, with a total value of $256,050.00. Following the completion of the acquisition, the chief executive officer now directly owns 846,638 shares of the company's stock, valued at approximately $4,817,370.22. This trade represents a 5.61 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 13.89% of the company's stock.

Wall Street Analyst Weigh In

ENTA has been the topic of several research analyst reports. StockNews.com upgraded shares of Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Wednesday, February 19th. JMP Securities reissued a "market outperform" rating and issued a $21.00 target price on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th. Finally, HC Wainwright reissued a "buy" rating and issued a $18.00 target price on shares of Enanta Pharmaceuticals in a research report on Tuesday, February 11th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $17.25.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.